Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive upper and lower motor neuron (MN) degeneration with unclear pathology. The worldwide prevalence of ALS is approximately 4.42 per 100,000 populations, and death occurs within 3–5 years after diagnosis. However, no effective therapeutic modality for ALS is currently available. In recent years, cellular therapy has shown considerable therapeutic potential because it exerts immunomodulatory effects and protects the MN circuit. However, the safety and efficacy of cellular therapy in ALS are still under debate. In this review, we summarize the current progress in cellular therapy for ALS. The underlying mechanism, current clinical trials, and the pros and cons of cellular therapy using different types of cell are discussed. In addition, clinical studies of mesenchymal stem cells (MSCs) in ALS are highlighted. The summarized findings of this review can facilitate the future clinical application of precision medicine using cellular therapy in ALS.

Original languageEnglish
Article number851613
JournalFrontiers in Cell and Developmental Biology
Publication statusPublished - Mar 16 2022


  • ALS
  • cellular therapy
  • mesenchymal stem cell
  • motor neuron degeneration
  • precision medicine

ASJC Scopus subject areas

  • Developmental Biology
  • Cell Biology


Dive into the research topics of 'Potential of Cellular Therapy for ALS: Current Strategies and Future Prospects'. Together they form a unique fingerprint.

Cite this